Change - Announcement of Appointment::APPOINTMENT OF EXECUTIVE DIRECTOR

Issuer & Securities

Issuer/ Manager
AOXIN Q & M DENTAL GRP LIMITED
Securities
AOXIN Q & M DENTAL GRP LIMITED - SG1DF9000000 - 1D4
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
02-Nov-2021 17:20:24
Status
New
Announcement Sub Title
APPOINTMENT OF EXECUTIVE DIRECTOR
Announcement Reference
SG211102OTHRFB44
Submitted By (Co./ Ind. Name)
SHAO YONGXIN
Designation
EXECUTIVE DIRECTOR AND GROUP CHIEF EXECUTIVE OFFICER
Description (Please provide a detailed description of the event in the box below)
Appointment of Executive Director - Ong Siew Hwa

This Announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, SAC Capital Private Limited (the "Sponsor"). This Announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("Exchange") and the Exchange assumes no responsibility for the contents of this Announcement, including the correctness of any of the statements or opinions made or reports contained in this Announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21-00, AIA Tower, Singapore 048542.

Additional Details

Date Of Appointment
01/11/2021
Name Of Person
ONG SIEW HWA
Age
49
Country Of Principal Residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)
Dr Ong Siew Hwa has been appointed as an Executive Director of the Company, as a condition to the acquisition by the Company of 49% of the issued and paid-up share capital of Acumen Diagnostics Pte. Ltd. ("ADL"). Dr Ong is currently the Chief Executive Officer of ADL.

The Board, upon recommendation of the Nominating Committee of the Company, has reviewed and considered the relevant qualifications, expertise and experiences of Dr Ong and approved her appointment as an Executive Director. On 29 October 2021, the Company has obtained the shareholders approval to the appointment of Dr Ong as an Executive Director.

Please refer to sections 5 and 9.5 of the circular of the Company dated 14 October 2021 (the "Circular") for more details.
Whether appointment is executive, and if so, the area of responsibility
Dr Ong is appointed as an Executive Director to inter alia oversee the overall management of the business of ADL and its subsidiaries.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Executive Director
Professional qualifications
- Doctor of Philosophy, National University of Singapore, Institute of Molecular and Cell Biology, A*STAR, Singapore

- Bachelor of Science (Honours), Department of Biochemistry, National University of Singapore
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
NIL
Conflict of interests (including any competing business)
NIL
Working experience and occupation(s) during the past 10 years
(i) Chief Executive Officer and Chief Scientist, Acumen Diagnostics Pte. Ltd.

(ii) Founder and Chief Executive Officer, Acumen Research Laboratories Pte. Ltd.

Please refer to sections 5.2 of the Circular for more details.
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
As at the date of appointment, Dr Ong holds 92,654,545 shares, representing approximately 18.21% of the share capital of the Company.
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
1. SME Centre @ SMF Pte. Ltd.
2. Acumen Holdings Pte. Ltd.
Present
Directorships:

1. Acumen Diagnostics Pte. Ltd.
2. Acumen Research Laboratories Pte. Ltd.

Other principal commitments:

Adjunct Assistant Professor, Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
Dr Ong will be attending Listed Entity Director Modules as prescribed by the SGX-ST as soon as she can, but no later than 1 year from the date of her appointment as a Director of the Company.
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)
N.A.